Cytosorbents Future Growth
Future criteria checks 2/6
Cytosorbents is forecast to grow earnings and revenue by 67.1% and 26.1% per annum respectively while EPS is expected to grow by 67.3% per annum.
Key information
67.1%
Earnings growth rate
67.3%
EPS growth rate
| Medical Equipment earnings growth | 12.7% |
| Revenue growth rate | 26.1% |
| Future return on equity | n/a |
| Analyst coverage | Low |
| Last updated | 02 May 2025 |
Recent future growth updates
Recent updates
FDA And Health Canada Decisions Will Advance DrugSorb-ATR Launch
Apr 11 Regulatory decisions on DrugSorb-ATR could drive significant revenue growth, especially in the U.S. and Canada, with a large market opportunity.Further Upside For Cytosorbents Corporation (NASDAQ:CTSO) Shares Could Introduce Price Risks After 28% Bounce
Jan 17
The Market Lifts Cytosorbents Corporation (NASDAQ:CTSO) Shares 43% But It Can Do More
Oct 01Investors Continue Waiting On Sidelines For Cytosorbents Corporation (NASDAQ:CTSO)
Jul 04Health Check: How Prudently Does Cytosorbents (NASDAQ:CTSO) Use Debt?
Mar 16Take Care Before Jumping Onto Cytosorbents Corporation (NASDAQ:CTSO) Even Though It's 28% Cheaper
Jan 06Is Cytosorbents (NASDAQ:CTSO) Using Too Much Debt?
Nov 10Shareholders Should Be Pleased With Cytosorbents Corporation's (NASDAQ:CTSO) Price
Jul 13Health Check: How Prudently Does Cytosorbents (NASDAQ:CTSO) Use Debt?
May 16We're A Little Worried About Cytosorbents' (NASDAQ:CTSO) Cash Burn Rate
Mar 08Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2027 | 65 | -1 | N/A | N/A | 2 |
| 12/31/2026 | 50 | -8 | N/A | N/A | 3 |
| 12/31/2025 | 41 | -15 | N/A | N/A | 3 |
| 12/31/2024 | 36 | -21 | -15 | -14 | N/A |
| 9/30/2024 | 38 | -19 | -19 | -18 | N/A |
| 6/30/2024 | 37 | -26 | -22 | -21 | N/A |
| 3/31/2024 | 37 | -28 | -24 | -23 | N/A |
| 12/31/2023 | 31 | -29 | -23 | -22 | N/A |
| 9/30/2023 | 37 | -23 | -22 | -21 | N/A |
| 6/30/2023 | 36 | -26 | -24 | -22 | N/A |
| 3/31/2023 | 35 | -31 | -30 | -23 | N/A |
| 12/31/2022 | 35 | -33 | -35 | -28 | N/A |
| 9/30/2022 | 36 | -41 | -36 | -28 | N/A |
| 6/30/2022 | 38 | -36 | -34 | -26 | N/A |
| 3/31/2022 | 41 | -29 | -24 | -20 | N/A |
| 12/31/2021 | 43 | -25 | -18 | -14 | N/A |
| 9/30/2021 | 44 | -16 | -12 | -10 | N/A |
| 6/30/2021 | 45 | -10 | -11 | -9 | N/A |
| 3/31/2021 | 43 | -9 | -7 | -5 | N/A |
| 12/31/2020 | 41 | -8 | -7 | -6 | N/A |
| 9/30/2020 | 36 | -11 | -10 | -9 | N/A |
| 6/30/2020 | 32 | -17 | -12 | -11 | N/A |
| 3/31/2020 | 28 | -18 | -17 | -16 | N/A |
| 12/31/2019 | 25 | -19 | -18 | -17 | N/A |
| 9/30/2019 | 24 | -21 | -17 | -15 | N/A |
| 6/30/2019 | 23 | -17 | -14 | -13 | N/A |
| 3/31/2019 | 23 | -19 | -14 | -13 | N/A |
| 12/31/2018 | 23 | -17 | -12 | -11 | N/A |
| 9/30/2018 | 21 | -15 | N/A | -9 | N/A |
| 6/30/2018 | 19 | -14 | N/A | -8 | N/A |
| 3/31/2018 | 17 | -10 | N/A | -7 | N/A |
| 12/31/2017 | 15 | -9 | N/A | -6 | N/A |
| 9/30/2017 | 14 | -11 | N/A | -7 | N/A |
| 6/30/2017 | 12 | -10 | N/A | -7 | N/A |
| 3/31/2017 | 11 | -11 | N/A | -7 | N/A |
| 12/31/2016 | 10 | -12 | N/A | -7 | N/A |
| 9/30/2016 | 8 | -9 | N/A | -8 | N/A |
| 6/30/2016 | 7 | -10 | N/A | -8 | N/A |
| 3/31/2016 | 6 | -5 | N/A | -8 | N/A |
| 12/31/2015 | 5 | -9 | N/A | -9 | N/A |
| 9/30/2015 | 4 | -17 | N/A | -9 | N/A |
| 6/30/2015 | 4 | -17 | N/A | -9 | N/A |
| 3/31/2015 | 4 | -21 | N/A | -8 | N/A |
| 12/31/2014 | 4 | -19 | N/A | -6 | N/A |
| 9/30/2014 | 4 | -9 | N/A | -5 | N/A |
| 6/30/2014 | 4 | -8 | N/A | -4 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: CTSO is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: CTSO is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: CTSO is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: CTSO's revenue (26.1% per year) is forecast to grow faster than the US market (8.4% per year).
High Growth Revenue: CTSO's revenue (26.1% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if CTSO's Return on Equity is forecast to be high in 3 years time
Discover growth companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/05/05 15:18 |
| End of Day Share Price | 2025/05/02 00:00 |
| Earnings | 2024/12/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Cytosorbents Corporation is covered by 8 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Jonathan Aschoff | Brean Capital |
| Jason Kolbert | D. Boral Capital LLC. |
| Sean Lee | H.C. Wainwright & Co. |